Nycomed Imaging As

Nabriva Therapeutics Ag

Ariva Med Gmbh

Nabriva Therapeutics Gmbh

Hermann Kollmann

Alan Cuthbertson

Peter Kremminger

Franz Rovenszky

Michael Hartmann

Johann Hiebl

Klaus Thirring

Peter Fischer

Mette Husbyn

Rosemarie Riedl

Jessie Sandosham

Susanne Paukner

Wolfgang Wicha

Werner Heilmayer

Dirk B Strickmann

Zrinka Ivezic-Schoenfeld

Josef Wieser

Dirk Strickmann

A compound of compound according to formula (I): wherein X is selected from the group consisting of CH, CCl and N, Z is selected from the group consisting of CHCOOH, CH(CH)COOH, C(CH)COOH and CHF, D is a single bond connecting A and Ar or selected from the group consisting of CO, NHCO and N(C)alkyl-CO, A is selected from the group consisting of a (C)alkanediyl and a (C)cycloalkanediyl or, if D is N(C)alkyl-CO, A forms a 4- to 7-membered aliphatic heterocyclic ring with the nitrogen atom of N(C)alkyl-CO in D, and Ar is a 6-membered aromatic ring with a first hydroxyl group in para-position to D, a second hydroxyl group in meta-position to D, and with at least one electron-withdrawing element and uses thereof.

Siderophore cephalosporin conjugates and uses thereof

A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a salt and/or solvate, wherein the naturally occurring pleuromutilin is of formula processes for the preparation of such compounds and their use as pharmaceuticals.

12-epi pleuromutilins

The present invention relates to novel pyrazine compounds and their use in the regulation of haematopoiesis, in particular in the stimulation of haematopoiesis, and in the treatment of bacterial, viral and fungal diseases.

Pyrazinedicarboxylic-acid derivatives as cell proliferation regulators

Pyrazine fused to a cyclic peptide

Growing community of inventors

Linz, Austria

Hermann Kollmann